Innovimmune Biotherapeutics

Innovimmune Biotherapeutics is a New York-based biotech founded in 2017, leveraging a proprietary structure-guided and fragment-based drug design platform to develop oral small-molecule immunotherapies. The company's core strategy is its 'pipeline in a molecule' R&D model, aiming to advance single clinical candidates across multiple disease areas in parallel. With a seasoned team from major pharma and active academic collaborations, Innovimmune is positioned to pursue high-value but historically difficult-to-drug targets in immunology and oncology. The company is currently in the preclinical discovery and development stage.

Structure-guided and fragment-based drug design platform utilizing computational machine learning, AI, and structural biology to target intractable disease-associated proteins and develop oral small-molecule NCEs with Lipinski Rule-of-Five compliance.

Operates in the highly competitive fields of immuno-oncology and autoimmune therapeutics, competing against large pharmaceutical companies and numerous biotechs developing both biologic and small-molecule immunomodulators. Differentiation is sought through a platform focused on historically intractable targets and an oral administration route.